| UHC Commercial Medical & Drug | Ryplazim® (Plasminogen, Human-Tvmh) – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Screening Colonoscopy Procedures – Site of Service – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Surgery of the Hip – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Tocilizumab (Actemra®, Tofidence®, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Treatment of Temporomandibular Joint Disorders – Commercial and Individual Exchange Medical Policy | 2026-03-01 |
| BCBS Premera WA AK Clinical | Sacral Nerve Neuromodulation/Stimulation | 2026-03-01 |
| BCBS Premera WA AK Clinical | Occipital Nerve Stimulation | 2026-03-01 |
| BCBS Premera WA AK Clinical | Responsive Neurostimulation for the Treatment of | 2026-03-01 |
| BCBS Premera WA AK Clinical | Implantable Peripheral Nerve Stimulation for the | 2026-03-01 |